Infectious Endophthalmitis in Boston Keratoprosthesis: Incidence and Prevention
Acta Ophthalmologica 2014 Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention Irmgard Behlau,1,2,3,4 Kathryn V. Martin,1,* Jacqueline N. Martin,1,* Elena N. Naumova,5 James J. Cadorette,6 J. Tammy Sforza,7 Roberto Pineda II1 and Claes H. Dohlman1 1Ophthalmology, Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA 2Molecular Biology & Microbiology and Ophthalmology, Tufts-Sackler Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA 3Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Mount Auburn Hospital, Cambridge, Massachusetts, USA 4Division of Infectious Diseases, Department of Medicine, Tufts University School of Medicine, Newton-Wellesley Hospital, Newton, Massachusetts, USA 5Tufts Initiative for Forecasting and Modeling of Infectious Diseases (InForMID), School of Engineering, Tufts University, Medford, Massachusetts, USA 6Henry Whittier Porter Bacteriology Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA 7Pharmacy Department, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA ABSTRACT. Introduction Purpose: To determine the cumulative worldwide incidence of infectious endoph- For the 4–8 million persons who are thalmitis and associated vision loss after Boston keratoprosthesis (B-KPro) Type I/II blind from corneal disease worldwide implantation and to propose both safe and inexpensive prophylactic antibiotic regimens. Methods: (Smith & Taylor 1999; Mariotti 2010; Two retrospective methods were used to determine the incidence, visual Silva et al. 2006) and who cannot be outcomes and aetiologies of infectious endophthalmitis associated with the B-KPro helped by standard corneal transplan- divided per decade: (i) systematic review of the literature from 1990 through January tation (Garg et al.
[Show full text]